Sayda Mahgoub Elbashir

USPTO Granted Patents = 56 (Patent Applications = 40)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 3.7

ph-index = 27

Forward Citations = 2,868(Granted Patents)

Forward Citations (Not Self Cited) = 2,676(Oct 12, 2025)

Inventors with similar research interests:

Company Filing History:

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

patents

14 out of 8,369

Massachusetts Institute of Technology

patents

4. 14 out of 1,551

University of Massachusetts

patents

5. 13 out of 303

Whitehead Institute for Biomedical Research

patents

6. 8 out of 34

Moderna Therapeutics, Inc.

patents

7. 7 out of 443

Alnylam Pharmaceuticals, Inc.

patents

8. 1 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

9. 1 out of 1

Whitehead Institute of Biomedical Technology

patent

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12419957 - Delivery and formulation of engineered nucleic acids (2025-09-23),

2. 12409226 - Delivery and formulation of engineered nucleic acids (2025-09-09),

3. 12364763 - Delivery and formulation of engineered nucleic acids (2025-07-22),

4. 12070495 - HIV RNA vaccines (2024-08-27),

5. 11911474 - Delivery and formulation of engineered nucleic acids (2024-02-27),

6. 11643441 - Nucleic acid vaccines for varicella zoster virus (VZV) (2023-05-09),

7. 11603399 - Long-lived polynucleotide molecules (2023-03-14),

8. 11364292 - CHIKV RNA vaccines (2022-06-21),

9. 11235052 - Chikungunya virus RNA vaccines (2022-02-01),

10. 10898574 - Delivery and formulation of engineered nucleic acids (2021-01-26),

11. 10772975 - Modified Polynucleotides for the production of biologics and proteins associated with human disease (2020-09-15),

12. 10702597 - CHIKV RNA vaccines (2020-07-07),

13. 10675342 - Chikungunya virus RNA vaccines (2020-06-09),

14. 10633656 - RNA interference mediating small RNA molecules (2020-04-28),

15. 10238731 - Chikagunya virus RNA vaccines (2019-03-26),

Title: The Innovation Journey of Inventor Sayda Mahgoub Elbashir

Introduction:

Sayda Mahgoub Elbashir, a prolific inventor based in Cambridge, MA, has made significant contributions to the field of biotechnology with his remarkable portfolio of 51 patents.

Latest Patents:

1. Nucleic acid vaccines for varicella zoster virus (VZV): Elbashir's groundbreaking work involves nucleic acid vaccines for VZV, incorporating RNA polynucleotides encoding VZV antigens. The patents outline methods for vaccine preparation and usage.

2. Long-lived polynucleotide molecules: Elbashir's invention focuses on the therapeutic use and preparation of long-lived polynucleotides, primary transcripts, and mmRNA molecules.

Career Highlights:

Elbashir has left an indelible mark in companies like Moderna Inc. and the Massachusetts Institute of Technology, where his innovative spirit and expertise have been instrumental in pushing the boundaries of biotechnological advancements.

Collaborations:

Throughout his career, Elbashir has collaborated closely with esteemed colleagues such as Antonin de Fougerolles and Jason P. Schrum, fostering a culture of innovation and excellence in his research endeavors.

Conclusion:

In conclusion, Sayda Mahgoub Elbashir's exceptional talent and dedication to innovation have not only yielded an impressive patent portfolio but have also paved the way for groundbreaking advancements in the realm of biotechnology. His contributions continue to inspire future generations of inventors and researchers in the field.

This text is generated by artificial intelligence and may not be accurate.